1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Newron Points ‘Future Value-Driver’ Evenamide At Drug-Resistant Schizophrenia

Following Phase II Promise

 
• By Ayisha Sharma

The Italian firm’s VGSC-blocker has demonstrated long-term symptom improvement in a mid-stage trial in drug-resistant schizophrenia, expediting Phase III development plans that could help address a high unmet need.  

One head split into two faces, one red and one blue, representing concept of schizophrenia
Schizophrenia Affects Around 24 Million People Worldwide • Source: Shutterstock

Newron Pharmaceuticals S.p.A.’s evenamide has shown signs of long-term safety and efficacy as an add-on therapy in a Phase II treatment-resistant schizophrenia (TRS) trial, sparking the advancement of pivotal development for the key value driver.

Evenamide blocks voltage-gated sodium channels (VGSCs), which is theorized to normalize glutamate release induced by aberrant sodium channel activity without...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.